HRP20151334T1 - Derivat kateholamina koristan u lijeäśenju parkinsonove bolesti - Google Patents

Derivat kateholamina koristan u lijeäśenju parkinsonove bolesti Download PDF

Info

Publication number
HRP20151334T1
HRP20151334T1 HRP20151334TT HRP20151334T HRP20151334T1 HR P20151334 T1 HRP20151334 T1 HR P20151334T1 HR P20151334T T HRP20151334T T HR P20151334TT HR P20151334 T HRP20151334 T HR P20151334T HR P20151334 T1 HRP20151334 T1 HR P20151334T1
Authority
HR
Croatia
Prior art keywords
substance
treatment
disorder
disease
pharmaceutically acceptable
Prior art date
Application number
HRP20151334TT
Other languages
English (en)
Croatian (hr)
Inventor
Morten JØRGENSEN
Benny Bang-Andersen
Ask Püschl
Niels MØRK
Jennifer Larsen
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39877715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20151334(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of HRP20151334T1 publication Critical patent/HRP20151334T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/08—Aza-anthracenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Portable Nailing Machines And Staplers (AREA)
  • Indole Compounds (AREA)
HRP20151334TT 2007-08-31 2008-08-28 Derivat kateholamina koristan u lijeäśenju parkinsonove bolesti HRP20151334T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200701250 2007-08-31
EP08784472.6A EP2197883B1 (en) 2007-08-31 2008-08-28 Catecholamine derivative useful for the treatment of parkinson's disease
PCT/DK2008/050214 WO2009026934A1 (en) 2007-08-31 2008-08-28 Catecholamine derivatives useful for the treatment of parkinson' s disease

Publications (1)

Publication Number Publication Date
HRP20151334T1 true HRP20151334T1 (hr) 2016-01-01

Family

ID=39877715

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20151334TT HRP20151334T1 (hr) 2007-08-31 2008-08-28 Derivat kateholamina koristan u lijeäśenju parkinsonove bolesti

Country Status (29)

Country Link
EP (4) EP2195291A1 (enExample)
JP (4) JP5548125B2 (enExample)
KR (3) KR20100051834A (enExample)
CN (3) CN101687878A (enExample)
AR (2) AR068044A1 (enExample)
AU (2) AU2008291425B2 (enExample)
BR (2) BRPI0813456A2 (enExample)
CA (2) CA2697688A1 (enExample)
CL (2) CL2008002564A1 (enExample)
CO (2) CO6270232A2 (enExample)
CY (1) CY1117326T1 (enExample)
DK (1) DK2197883T3 (enExample)
EA (2) EA018011B1 (enExample)
ES (1) ES2557485T3 (enExample)
HR (1) HRP20151334T1 (enExample)
HU (1) HUE025882T2 (enExample)
IL (1) IL203080A (enExample)
MX (1) MX2010002210A (enExample)
MY (2) MY148948A (enExample)
NZ (2) NZ583551A (enExample)
PL (1) PL2197883T3 (enExample)
PT (1) PT2197883E (enExample)
RS (1) RS54470B1 (enExample)
SG (1) SG184711A1 (enExample)
SI (1) SI2197883T1 (enExample)
TW (2) TWI404702B (enExample)
UA (2) UA97989C2 (enExample)
WO (2) WO2009026934A1 (enExample)
ZA (2) ZA200909191B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
US8067410B2 (en) 2008-06-27 2011-11-29 H. Lundbeck A/S Phenolic and catecholic amines and prodrugs thereof
WO2009156458A1 (en) * 2008-06-27 2009-12-30 H. Lundbeck A/S Novel phenolic and catecholic amines and prodrugs thereof
TW201036949A (en) * 2009-02-27 2010-10-16 Lundbeck & Co As H Treatment of dyskinesia related disorders
TW201035054A (en) * 2009-02-27 2010-10-01 Lundbeck & Co As H Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
TWI816716B (zh) 2017-11-24 2023-10-01 丹麥商Ｈ 朗德貝克公司 用於治療帕金森病之新兒茶酚胺前驅藥
WO2020070099A1 (en) 2018-10-02 2020-04-09 H. Lundbeck A/S Administration of catecholamine prodrugs in combination with a 5-ht2b antagonist
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) * 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
EP3972959A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
US12319710B2 (en) 2019-05-21 2025-06-03 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's diseases
US12384765B2 (en) 2019-05-21 2025-08-12 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's Disease
CN113727712B (zh) * 2019-05-21 2024-11-15 H.隆德贝克有限公司 用于治疗帕金森病的儿茶酚胺氨基甲酸酯前药
CN114478298B (zh) * 2020-11-12 2024-09-27 成都西岭源药业有限公司 一种造影剂碘佛醇的纯化方法
EP4247793A1 (en) * 2020-11-17 2023-09-27 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
CN113620760A (zh) * 2021-09-07 2021-11-09 张家口思睿凯科技有限公司 一种电子盐反应液和不饱和芳香烃类化合物的还原方法
WO2025078574A1 (en) * 2023-10-12 2025-04-17 Integrative Research Laboratories Sweden Ab NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080456A (en) * 1971-10-26 1978-03-21 Schering Aktiengesellschaft Diacylapomorphines
CH648300A5 (en) * 1979-06-22 1985-03-15 Sandoz Ag Phenanthrene derivatives and medicaments containing them
US4543256A (en) * 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
WO1990012574A1 (en) * 1989-04-25 1990-11-01 Northeastern University Dopamine agonist compounds
JPH03163078A (ja) * 1989-08-30 1991-07-15 Sankyo Co Ltd 光学活性な縮環複素環化合物及びその製法
TW357143B (en) * 1995-07-07 1999-05-01 Novartis Ag Benzo[g]quinoline derivatives
JPH11515030A (ja) * 1995-11-10 1999-12-21 ノボ ノルディスク アクティーゼルスカブ シス−ベンズ［ｅ］インドール化合物のエナンチオマー、これらの製造、及びドーパミン−Ｄ３受容体選択的医薬としての利用
CN1241998A (zh) * 1996-10-30 2000-01-19 伊莱利利公司 苯并[f]喹啉酮的合成
SE0002934D0 (sv) 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
SE0102036D0 (sv) 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
AR030357A1 (es) * 2000-08-18 2003-08-20 Lundbeck & Co As H Derivados 4 -, 5 -, 6 - y 7-indol
US20050090518A1 (en) * 2003-10-24 2005-04-28 Nastech Pharmaceutical Company Inc. Method for treating parkinson's disease using apomorphine and apomorphine prodrugs
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥

Also Published As

Publication number Publication date
WO2009026935A1 (en) 2009-03-05
CN107253956A (zh) 2017-10-17
PL2197883T3 (pl) 2016-03-31
TWI404702B (zh) 2013-08-11
ES2557485T3 (es) 2016-01-26
EA200971107A1 (ru) 2010-06-30
TW200911752A (en) 2009-03-16
CL2008002558A1 (es) 2009-08-07
JP5548125B2 (ja) 2014-07-16
AR068045A1 (es) 2009-10-28
KR101597367B1 (ko) 2016-02-24
EA201070327A1 (ru) 2010-08-30
IL203080A (en) 2014-11-30
JP5802792B2 (ja) 2015-11-04
HUE025882T2 (en) 2016-04-28
UA98804C2 (ru) 2012-06-25
EP2662358A1 (en) 2013-11-13
EP2197883B1 (en) 2015-11-18
MY179527A (en) 2020-11-10
DK2197883T3 (en) 2016-01-11
UA97989C2 (uk) 2012-04-10
AU2008291425B2 (en) 2012-12-06
JP2014111635A (ja) 2014-06-19
WO2009026934A1 (en) 2009-03-05
PT2197883E (pt) 2016-02-02
CA2697688A1 (en) 2009-03-05
CN101687878A (zh) 2010-03-31
BRPI0813456A2 (pt) 2014-12-23
CA2691961A1 (en) 2009-03-05
AU2008291426A1 (en) 2009-03-05
AR068044A1 (es) 2009-10-28
SI2197883T1 (sl) 2016-01-29
AU2008291425A1 (en) 2009-03-05
CY1117326T1 (el) 2017-04-26
EP3009437A1 (en) 2016-04-20
SG184711A1 (en) 2012-10-30
MY148948A (en) 2013-06-14
KR20150115963A (ko) 2015-10-14
JP2010536889A (ja) 2010-12-02
NZ582379A (en) 2011-08-26
BRPI0815894A2 (pt) 2015-02-24
ZA201001422B (en) 2011-06-29
AU2008291426B2 (en) 2013-01-31
EA018413B1 (ru) 2013-07-30
CN101842354A (zh) 2010-09-22
CL2008002564A1 (es) 2009-07-17
RS54470B1 (sr) 2016-06-30
EP2197883A1 (en) 2010-06-23
CA2691961C (en) 2013-12-17
ZA200909191B (en) 2011-03-30
MX2010002210A (es) 2010-03-17
EA018011B1 (ru) 2013-04-30
TW200914426A (en) 2009-04-01
KR20100051834A (ko) 2010-05-18
JP2010536890A (ja) 2010-12-02
NZ583551A (en) 2012-07-27
CO6260082A2 (es) 2011-03-22
KR20100046111A (ko) 2010-05-06
EP2195291A1 (en) 2010-06-16
JP2014148528A (ja) 2014-08-21
CO6270232A2 (es) 2011-04-20

Similar Documents

Publication Publication Date Title
HRP20151334T1 (hr) Derivat kateholamina koristan u lijeäśenju parkinsonove bolesti
CO6362014A2 (es) Compuestos con anillos espiro - triciclicos como moduladores de beta-secretasaa y metodos de uso
EA201071298A1 (ru) Соединение 3-аминокарбазола, фармацевтическая композиция, его содержащая, и способ их получения
UY30411A1 (es) Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
PA8627201A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
JP2015512951A5 (enExample)
CY1114329T1 (el) Νεοι προσδετες υποδοχεων αδενοσινης και χρησεις εξ' αυτων
CL2012000185A1 (es) Compuestos derivados de oxazina o oxazepina, inhibidores de bace; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del deterioro cognitivo, neuropatia amiloide, o enfermedad de alzheimer.
DOP2012000167A (es) Moduladores alostericos positivos de receptores m1 de la quinolina amida
UY30414A1 (es) Metano sulfonatos, propano-1-sulfonatos y ciclopropan sulfonatos sustituidos con [2,3,4,8-tetrahidroimidazo-[1,5-al-pirimidin-8-il]-fenilo, composiciones farmacéuticas conteniéndolos y aplicaciones.
CY1116699T1 (el) Παραγωγα αλφα-αμινοαμιδιου τα οποια ειναι χρησιμα στην αγωγη γνωστικων διαταραχων
ECSP14013221A (es) Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento.
BR112017022568A2 (pt) compostos e seus usos como inibidores de bace1
EP2312946A4 (en) PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER
SG11201407973SA (en) Prodrug of fluorine-containing amino acid
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
EA201691831A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
JP2015521642A5 (enExample)
UA109414C2 (uk) Арильовані камфени та фармацевтична композиція на їх основі
CO6331428A2 (es) Compuestos que comprenden un grupo ciclobutoxi
EA201691788A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
CL2007002768A1 (es) Compuestos derivados de quinolin-amina; proceso de preparacion de dichos compuestos; medicamento; y uso para el tratamiento de enfermedades tales como depresion, trastornos de ansiedad, esquizofrenia, agorafobia, dolor, demencia y enfermedad de parki
EP2328877A4 (en) 1,4-BENZOXAZINE COMPOUNDS AND DERIVATIVES THEREOF AS THERAPEUTIC ACTIVITIES FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
MX377195B (es) Derivados de morfolina-piridina.